binx health, LTD.

binx health is a molecular diagnostics company specializing in point-of-care testing platforms for sexually transmitted infections and other infectious diseases. The company's flagship product, binx io, is an FDA-cleared, CLIA-waived molecular platform enabling single-visit diagnosis and treatment of chlamydia and gonorrhea infections with 30-minute time-to-results. binx io delivers rapid molecular diagnostics in clinical settings including urgent care, primary care clinics, sexual health clinics, and community health centers, supporting both male and female patients. The platform has established reimbursement pathways and is distributed nationally through partnerships with major healthcare distributors including Cardinal Health and Afaxys. binx health also developed binx everywhere, an at-home self-collection testing platform for STI and HPV screening. The company operates a reagent rental model and supplies molecular reagents to decentralized testing locations. binx health's point-of-care diagnostic solutions are designed to expand equitable access to healthcare, reduce traditional barriers to care, and enable rapid diagnosis-and-treatment workflows in community settings. The company has received regulatory clearance, strategic partnerships with healthcare systems, nonprofit organizations, and public health agencies, and recognition as a digital health innovator.